Previous 10 | Next 10 |
2023-08-01 10:23:02 ET Tyra Biosciences ( NASDAQ: TYRA ) said that the US Food and Drug Administration has granted orphan drug status to its lead drug candidate TYRA-300 in the treatment of achondroplasia, the most common form of dwarfism. The biotech company said it is prepar...
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia PR Newswire CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing...
2023-06-01 05:25:45 ET Summary TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet. Tyra Biosciences ( TYRA ) develops precision medicines usin...
2023-05-04 18:14:03 ET Tyra Biosciences press release ( NASDAQ: TYRA ): Q1 GAAP EPS of -$0.28 beats by $0.09 . As of March 31, 2023, TYRA had cash and cash equivalents of $241.7 million that will support TYRA through important clinical and operational milestones over a...
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights PR Newswire -SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track ...
Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire CARLSBAD, Calif. , March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medic...
2023-03-22 17:10:37 ET Tyra Biosciences press release ( NASDAQ: TYRA ): Q4 GAAP EPS of -$0.31 beats by $0.05 . Alan Fuhrman, CFO of TYRA, added, "TYRA is in a very strong financial position to begin 2023, with $251.2 million in cash and cash equivalents at year-end 202...
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights PR Newswire -Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondrop...
2023-03-10 11:41:50 ET Gainers: Euda Health ( EUDA ) +53% . Unicycive ( UNCY ) +27% . Tenon Medical ( TNON ) +12% . Rain ( RAIN ) +11% . Altamira ( CYTO ) +11% . Losers: Meihua International ( MHUA ) -34% . Fr...
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia PR Newswire - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned t...
News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Inc. Company Name:
TYRA Stock Symbol:
OTCMKTS Market:
Tyra Biosciences Inc. Website:
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...
NEW YORK, NY / ACCESSWIRE / April 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information an...